Predicting outcome in ankylosing spondylitis

Rheumatology

Volumn 47, Issue 7, 2008, Pages 942-945

  Pradeep, D John ^a   Keat, A ^b   Gaffney, K ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HLA B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; CLINICAL TRIAL; COXITIS; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; LABORATORY TEST; LIFESTYLE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SCORING SYSTEM; SEX DIFFERENCE; SOCIAL STATUS; SPINE RADIOGRAPHY;

ANTIRHEUMATIC AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45749121136     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken195     Document Type: Editorial

References (60)

1. Khan MA. Ankylosing spondylitis: Clinical aspects. In: Calin A, Taurog J, ads. The spondyloarthritides. Oxford: Oxford University Press, 1998.
2. Van der Heijde D, Djikmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
3. Davis JC Jr, Van der Heijde D, Braun J et al. Enbrel ankylosing spondylitis study group. Recombinant human tumour necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized controlled trial. Arthritis Rheum 2003;48:3230-6.
4. Van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicentre, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
5. Davis JC, van der Heijde, Dougadaos M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
6. Davis JC Jr, Revicki D, van der Heijde DM et al. Health-related quality of health outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. Arthritis Rheum 2007;57:1050-7.
7. Braun J, Baralikos X, Brandt J et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 2005;44:670-6.
8. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003;29:185-202.
9. Baralikos X, Listing J, Rudwaleit M et al. Radiographic progression in patients with ankylosing spondylitis after2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-6.
10. Jois RN, Gaffney K, Kest A. Anti-tumour necrosis factor therapy for ankylosing spondylitis-unresolved issues. Rheumatology 2007;46:899-901.
11. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson I, Calin A, Braun J. The burden of ankylosing spondylitis and the cost effectiveness of treatment with infliximab. Rheumatology 2004;43:1158-66.
12. Robertson LP, Davis MJ. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology 2004;43:1565-8.
13. Goei The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A comparison of the Rome, New York and modified New York criteria in patients with a positive screening test for ankylosing spondylitis. Br J Rheumatol 1985;24:242-9.
14. Rudwaleit M, Listing J, Marker-Hermann E et al. spinal mobility in early ankylosing spondylitis and in axial SpA without definite radiographic sacroillitis. Ann Rheum Dis 2004;63(Suppl 1):400.
15. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Seiper J. How to diagnose axial spondyloarthritis early? Ann Rheum Dis 2004;63:535-43.
16. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
17. Schett G, Landewe R, van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: What is reality and what is fiction? Ann Rheum Dis 2007;66:709-11.
18. Calabro J, Amante CM. Prognosis in ankylosing spondylitis. Arthritis Rheum 1969;8:471.
19. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: A study of 100 patients. Br J Rheumatol 1997;36:766-71.
20. Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum 1983;26:186-90.
21. Stone MA, Pomeroy E, Kest A et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Stone MAN illustration. Rheumatology 2008; doi: 10.1093/rheumatology/ken176.
22. van der Helm-van Mil AH, le Cessie S, van Dongen H, Breadveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patents with recent-onset undifferentiated arthritis: How to guide individual treatment decisions. Arthritis Rheum 2007;56:433-40.
23. Garret S, Jenkinson T, Kennedy LG, Whitefock H, Gainsford P, Calin A. A new approach to defining disease status in ankylosing spondylitis. The BATH Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
24. Calin A, Garret S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the BATH Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-85.
25. Jenkinson TR, Mallory PA, Whitelock HC, Kennedy LG, Garret SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
26. Creemers MC, Franssen MJ, vant Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: An extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
27. van der Heijde D, Landewe R, Hermann KG et al. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? J Rheumatol 2007;34:871-3.
28. Roussou E, Kennedy G, Garret S, Calin A. Socio-eoonomic status in ankylosing spondylitis: Relationship between occupation and disease activity. J Rheumatol 1997;24:908-11.
29. Marks SH, Barnett M, Calin A. A case-control study of juvenile and adult-onset ankylosing spondylitis. J Rheumatol 1982;9:739-41.
30. Hart FD, Robinson KC. Ankylosing spondylitis in women. Ann Rheum Dis 1959;18:15-23.
31. McBryde AM, McCollum DE. Ankylosing spondylitis in women. The disease and its prognosis. NC Med J 1973;34:34-7.
32. Braunstein EM, Martel W, Moidel R. Ankylosing spondylitis in men and women: A clinical and radiographic comparison. Radiology 1982;144:91-4.
33. Lee W, Reveille JD, Davis JC Jr, Learch TJ, Ward MM, Weisman MH. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis 2007;66:633-8.
34. Daltroy LH, Larson MG, Roberts NW, Liang MH. A modification of the health assessment questionnaire for the spondyloarthropahies. J Rheumatol 1990; 17:946-50.
35. Colin A, Mackay K, Santos H, Brophy S. A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. J Rheumatol 1999;26:988-92.
36. Amor B, Santos R, Nahal R, Listrat V, Dougados M. Predictive factors for the long-term outcome of spondyloarthropathies. J Rheumatol 1994;21:1883-7.
37. Wordsworth BP, Mowat AG. A review of 100 patients with ankylosing spondylitis with particular reference to socio-economic effects. Br J Rheumatol 1986;25:175-80.
38. Brophy S, Pavy S, Lewis P, Taylor G, Colin A. Inflammatory eye, skin and bowel disease in spondyloarthritis: Genetic, phenotypic and environmental factors. J Rheumatol 2001;28:2667-73.
39. Pavy S, Brophy S, Hickey S, Calin A. Iritis: Is it a predictor of long-term outcome in ankylosing spondylitis? Rheumatology 2002;41(Suppl 1):A306.
40. Hart F. Natural history and complications of ankylosing spondylitis. In: Moll J, ed. Ankylosing spondylitis. Edinburgh: Churchill Livingstone, 1980.
41. Avems H, Oxtoby J, Taylor H, Jones P, Dziedzic K, Dawes P. Smoking and outcome in ankylosing spondylitis. Scan J Rheumatol 1996;25:138-42.
42. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 2002;29:1420-5.
43. Guillemin F, Briancon S, Pourel J, Gaucher A. Long term disability and prolonged sick leaves as outcome measures in ankylosing spondylitis. Arthritis Rheum 1990; 33:1001-6.
44. Hammersma J, Cordon LR, Bradbury L et al. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum 2001;44:1396-400.
45. Doran MF, Brophy S, Mackay K, Taylor G, Calin A. Predictors of long term outcome in ankylosing spondylitis. J Rheumatol 2003;30:316-20.
46. Brown MA, Kennedy LG, Macgregor AJ et al. Susceptibility to ankylosing spondylitis in twins: The role of genes, HLA, and the environment. Arthritis Rheum 1997; 40:1823-8.
47. Brown MA, Pile KD, Kennedy LG et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum 1998;41:588-95.
48. Brown MA. Breakthroughs in genetic studies of ankylosing spondylitis. Rheumatology 2008;47:132-7.
49. Van der Heijde D, Wanders A, Mielants H, Dougados M, Landewe RBM. Prediction of progression of radiographic damage over 4 years in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2004;63(Suppl 1):98.
50. Braun J, Bollow M, Eggens U, Konig H, Distler A, Seiper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroillitis in spondyloarthropathy patients. Arthritis Rheum 1994;37:1039-45.
51. Rouf J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: A literature review. J Rheumatology 1999;26:966-70.
52. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicenter trial. Lancet 2002;359:1187-93.
53. Braun J, Brandt J, Listing J et al. Long term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized controlled trial. Arthritis Rheum 2003;48:2224-33.
54. Rudawaleit M, Listing J, Brandt J, Braun J, Seiper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
55. Tan AL, Marzo-Ortega S, O'Connor P, Fraser A, Emery P, Mc Gonagle D. Efficacy of anakinra in active ankylosing spondylitis: A clinical and magnetic resonance imaging study. Ann Rheum Dis 2004;63:1041-5.
56. Haibel M, Rudawalait, Listing J, Seiper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64:296-8.
57. Vazaquez-Del M, Garcia-Gonzalez A, Munoz-Valle JF et al. Interleukin 1 beta (IL-1 beta), IL-10, tumour necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol 2002;29:522-6.
58. Bennett AN, Tan AL, Coates C, Emery P, Marzo-Ortega H, McGonagle D. Sustained response to anakinra in ankylosing spondylitis. Rheumatology 2008;47:223-4.
59. Visvanathan S, Wagner CL, Marini JC et al. Inflammatory biomarkers, disease activity, and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67:511-7.
60. Mader R. Atypical clinical presentation of ankylosing spondylitis. Semin Arthritis Rheum 1999;29:191-6.